This is a definitive win for VTRS, the Federal Circuit's affirmance is the final word on patent infringement for this ANDA. Expect VTRS to receive FDA approval for its generic epoprostenol and launch imminently, capturing share in a branded market. Monitor FDA approval status and launch timing. The stock should re-rate upward as this multi-year patent risk is fully resolved.
VTRS drugs
VTRS drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 13 $17.37entry
- T+1 · 6mo ago −0.63%α −1.41% · $17.26
- T+5 · 6mo ago −6.91%α −5.75% · $16.17
- T+20 · 5mo ago −6.10%α −5.49% · $16.31
- T+60 · 3mo ago −5.41%α −9.85% · $16.43
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
The Federal Circuit affirmed the district court's ruling that Mylan Pharmaceuticals does not infringe Actelion's patents covering epoprostenol (Veletri®). The court upheld the construction that 'pH of 13 or higher' means measured at standard temperature (25±2°C), and Mylan's refrigerated bulk solution, with pH below 12.98 at that temperature, does not literally infringe. Actelion's doctrine-of-equivalents arguments were also barred by prosecution history estoppel and disclosure-dedication rules. This removes a material patent risk for VTRS, clearing the path for its generic epoprostenol ANDA.
Court Ruling Details
Key Facts
- Federal Circuit affirmed non-infringement of Actelion's '802 and '227 patents covering epoprostenol (Veletri®) by Mylan's ANDA product
- Court upheld construction that 'pH of 13 or higher' refers to measurement at standard temperature (25±2°C), not at refrigerated operating temperature
- Mylan's bulk solution undisputedly has pH well below 12.98 at standard temperature, no literal infringement
- Doctrine-of-equivalents claims barred by both prosecution history estoppel (amendment from pH >12 to pH ≥13) and disclosure-dedication rule (specification disclosed pH 12-13 ranges but did not claim them)
- Ruling is final and not subject to further appeal (Federal Circuit is the appellate court for patent cases from district courts)
Financial Impact
Removes patent risk blocking Mylan's generic epoprostenol ANDA. Veletri® is Actelion's (now Johnson & Johnson) product; Mylan's generic would compete in a market with estimated annual U.S. sales in the hundreds of millions. No damages awarded against VTRS.
Risk Factors
- FDA could still delay or deny ANDA approval on non-patent grounds
- Actelion/Johnson & Johnson could seek Supreme Court certiorari (unlikely given no circuit split or novel legal question)
- Generic launch may face pricing pressure or supply constraints
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-3lnulh2x-VTRS |
Track record
22 reports on VTRS
3 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +16.85% at T+60 after the Aug 6, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 17, 2026today 8-K Neutral 4/10 Entry $20.51 Now $20.49 −0.10% settles Feb 16
- Nov 17, 2026today Press Release Neutral 4/10 Entry $20.89 Now $20.49 −1.91% settles Feb 16
- Nov 16, 20261d ago SC 13G/A Neutral 2/10 Entry $20.84 Now $20.49 −1.68% settles Feb 12
- Nov 6, 202611d ago SC 13G/A Neutral 2/10 Entry $19.91 Now $20.49 +2.91% settles Feb 4
- Nov 5, 202612d ago 8-K Mixed 6/10 Entry $18.97 Now $20.49 +8.01% settles Feb 3
- Nov 4, 202613d ago Press Release Neutral 2/10 Entry $19.22 Now $20.49 +6.61% settles Feb 2
- Oct 30, 202618d ago Press Release Bullish 6/10 Entry $19.04 Now $20.49 +7.64% settles Jan 28
- Oct 29, 202619d ago Institutional Cluster Bullish 4/10 Entry $19.20 Now $20.49 +6.72% settles Jan 27
- Oct 16, 20264w ago Press Release Bullish 6/10 Entry $18.26 Now $20.49 +12.21% settles Jan 14
- Oct 8, 20265w ago 8-K Bullish 7/10 Entry $17.44 Now $20.49 +17.49% settles Jan 5
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers